Amin M. Alousi

Dec 17, 2023 | nature.com | Philip L McCarthy |Amin M. Alousi |David Miklos |Ran Reshef |Richard T Maziarz |John Levine

AbstractIdentifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to identify new biomarker models to predict aGvHD and overall mortality. Two new biomarkers (Gal-3 and LAG-3), and previously identified biomarkers (ST2/IL33R, IL6, Reg3A, PD-1, TIM-3, TNFR1) were screened.